0.00Open4.30Pre Close0 Volume1 Open Interest33.50Strike Price0.00Turnover156.83%IV4.26%PremiumJul 26, 2024Expiry Date3.00Intrinsic Value100Multiplier1DDays to Expiry1.30Extrinsic Value100Contract SizeAmericanOptions Type-0.8177Delta0.0845Gamma8.97Leverage Ratio-0.2434Theta-0.0011Rho-7.33Eff Leverage0.0053Vega
Pfizer Stock Discussion
This treatment for patients with hemophilia A appears to have the efficacy and safety metrics in place to warrant a potential approval.
Notably, Sangamo’s candidate is being developed alongside $Pfizer(PFE.US)$ , adding a layer of clout to the R&D behind the prospective treatment.
Sneaking on the radar on a red day.
“Be Fearful When Others Are Greedy and Greedy When Others Are Fearful” – Warren Buffett
“Success means being very patient, but aggressive when it’s time.” – Charlie Munger
My previous posts,
I am looking forward to upcoming Fed cuts
Will Nvidia Pullback to 90 ?
$NVIDIA(NVDA.US)$ $iShares Russell 2000 ETF(IWM.US)$ $MarketAxess(MKTX.US)$ $Pfizer(PFE.US)$ $Vanguard Real Estate ETF(VNQ.US)$ $Global Payments(GPN.US)$
loading...
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US)$ Orforglipron and $Structure Therapeutics(GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
No comment yet